Health-related quality of life (HRQOL) is an important endpoint in cancer clinical trials and in cancer treatment in general; however, the meaningfulness of HRQOL scores may not be apparent to clinicians or researchers. Minimally important differences (MIDs) can enhance the interpretability of HRQOL scores by identifying differences likely to be meaningful to patients and clinicians. This article’s objective is to describe and provide examples of approaches we have used to identify MIDs for instruments in the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Distribution- and anchor-based approaches are described and illustrated. We also discuss the importance of assessing the appropriateness of anchors, and we provide suggestions for combining results into a single range of plausible MIDs. MIDs for FACIT instruments established to date are summarized, and general guidelines that can be used to estimate MIDs for other FACIT instruments are provided. Applications of MIDs in research are illustrated.
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
2.
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., et al. (1997). Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. Journal of Clinical Oncology, 15(3), 974-986.
3.
Cella, D. (1994). Quality of life: Concepts and definitions. Journal of Pain and Symptom Management, 9(3), 186-192.
4.
Cella, D. (Ed.). (2004). Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system, Version 4.1. Evanston, IL: Center on Outcomes, Research and Education (CORE) Evanston Northwestern Healthcare and Northwestern University.
5.
Cella, D., Eton, D. T., Fairclough, D. L., Bonomi, P., Heyes, A. E., Silberman, C., et al. (2002). What is a clinically meaningful change on the Functional Assessment of Cancer Therapy Lung (FACT-L): Results from the Eastern Cooperative Oncology Group (ECOG) Study 5592. Journal of Clinical Epidemiology, 55, 285-295.
6.
Cella, D., Eton, D. T., Lai, J. S., Peterman, A., & Merkel, D. E. (2002). Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue scales. Journal of Pain and Symptom Management, 24(6), 547-561.
7.
Cella, D., Hahn, E. A., & Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Quality of Life Research, 11(3), 207-221.
8.
Cella, D., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579.
9.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum.
10.
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56(5), 395-407.
11.
de Haes, J. C. (1988). Quality of life: Conceptual and theoretical considerations. In M. Watson, S. Greer, & C. Thomas (Eds.), Psychosocial oncology (pp. 61-70). Oxford, UK: Pergamon.
12.
Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures: Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S-158S.
13.
Elashoff, J. D. (2000). nQuery Advisor (4.0 ed.). Cork, Ireland: Statistical Solutions.
14.
Eton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., et al. (2004). A combination of distribution- and anchor-based approaches determined minimally important differences(MIDs) for four end points in a breast cancer scale. Journal of Clinical Epidemiology, 57(9), 898-910.
15.
Ferrell, B. R., Dow, K. H., Leigh, S., Ly, J., & Gulasekaram, P. (1995). Quality of life in long-term cancer survivors. Oncology Nursing Forum, 22(6), 915-922.
16.
Guyatt, G. H., Norman, G. R., Juniper, E. F., & Griffith, L. E. (2002). A critical look at transition ratings. Journal of Clinical Epidemiology, 55(9), 900-908.
17.
Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77(4), 371-383.
18.
Guyatt, G. H., Walter, S., & Norman, G. R. (1987). Measuring change over time: Assessing the usefulness of evaluative instruments. Journal of Chronic Diseases, 40(2), 171-178.
19.
Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., et al. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. Journal of Clinical Oncology, 21(11), 2138-2146.
20.
Hays, R. D., & Woolley, J. M. (2000). The concept of clinically meaningful difference in health-related quality-of-life research: How meaningful is it?Pharmacoeconomics, 18(5), 419-423.
21.
Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology, 59(1), 12-19.
22.
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407-415.
23.
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989). Effect sizes for interpreting changes in health status. Medical Care, 27(3 Suppl), S178-S189.
24.
Lydick, E., & Epstein, R. S. (1993). Interpretation of quality of life changes. Quality of Life Research, 2(3), 221-226.
25.
MAPI Research Institute. (2004). Quality of Life Instrument Database (QOLID). Lyon, France: MAPI Research Trust. Available at www.qolid.org/
26.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139-144.
27.
Patrick, D. L., Gagnon, D. D., Zagari, M. J., Mathijs, R., & Sweetenham, J. (2003). Assessing the clinical significance of health-related quality of life (HRQOL) improvements in anaemic cancer patients receiving epoetin alfa. European Journal of Cancer, 39(3), 335-345.
28.
Ringash, J., Bezjak, A., O’Sullivan, B., & Redelmeier, D. A. (2004). Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients. Quality of Life Research, 13(4), 725-733.
29.
Sloan, J., Vargas-Chanes, D., Kamath, C., Sargent, D., Novotny, P., Atherton, P., et al. (2003). Detecting worms, ducks and elephants: A simple approach for defining clinically relevant effects in quality-of-life measures. Journal of Cancer Integrative Medicine, 1(1), 41-47.
30.
Vickers, A. J. (2004). Statistical considerations for use of composite health-related quality-of-life scores in randomized trials. Quality of Life Research, 13(4), 717-723.
31.
Ward, W. L., Hahn, W. A., Mo, F., Hernandez, L., Tulsky, D. S., & Cella, D. (1999). Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Quality of Life Research, 8(3), 181-195.
32.
Webster, K., Cella, D., & Yost, K. (2003). The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.
33.
Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. Journal of the American Medical Association, 273(1), 59-65.
34.
Wyrwich, K. W., Nienaber, N. A., Tierney, W. M., & Wolinsky, F. D. (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Medical Care, 37(5), 469-478.
35.
Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999). Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. Journal of Clinical Epidemiology, 52(9), 861-873.
36.
Yost, K. J., Cella, D., Chawla, A., Holmgren, E., Eton, D. T., Ayanian, J. Z., et al. (2004). Estimating minimally important differences in the Functional Assessment of Cancer Therapy-Colorectal (FACT-C). Manuscript submitted for publication.
37.
Yost, K. J., Sorensen, M. V., Hahn, E. A., Glendenning, G. A., Gnanasakthy, A., & Cella, D. (in press). Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy - Biologic Response Modifiers (FACT - BRM) instrument. Value in Health.
